

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶: A61K 9/70</p>		<p>A1</p>	<p>(11) International Publication Number: WO 97/09970</p> <p>(43) International Publication Date: 20 March 1997 (20.03.97)</p>									
<p>(21) International Application Number: PCT/US96/14739</p>		<p>95129 (US). RAMDAS, Asha [IN/US]; 707 Continental Circle #326, Mountain View, CA 94040 (US).</p>										
<p>(22) International Filing Date: 13 September 1996 (13.09.96)</p>		<p>(74) Agents: REED, Dianne, E.; Reed & Robins L.L.P., Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US) et al.</p>										
<p>(30) Priority Data:</p> <table><tr><td>08/528,105</td><td>14 September 1995 (14.09.95)</td><td>US</td></tr><tr><td>08/581,128</td><td>29 December 1995 (29.12.95)</td><td>US</td></tr><tr><td>Not furnished</td><td>12 September 1996 (12.09.96)</td><td>US</td></tr></table>		08/528,105	14 September 1995 (14.09.95)	US	08/581,128	29 December 1995 (29.12.95)	US	Not furnished	12 September 1996 (12.09.96)	US	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
08/528,105	14 September 1995 (14.09.95)	US										
08/581,128	29 December 1995 (29.12.95)	US										
Not furnished	12 September 1996 (12.09.96)	US										
<p>(60) Parent Application or Grant</p> <p>(63) Related by Continuation</p> <table><tr><td>US</td><td>08/581,128 (CIP)</td></tr><tr><td>Filed on</td><td>29 December 1995 (29.12.95)</td></tr></table>		US	08/581,128 (CIP)	Filed on	29 December 1995 (29.12.95)	<p>Published</p> <p>With international search report.</p> <p>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>						
US	08/581,128 (CIP)											
Filed on	29 December 1995 (29.12.95)											
<p>(71) Applicant (for all designated States except US): CYGNUS, INC. [US/US]; 400 Penobscot Drive, Redwood City, CA 94063 (US).</p>												
<p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CHEN, Tung-Fen [US/US]; 1675 Hollenbeck Avenue #20, Sunnyvale, CA 94087 (US). CHIANG, Chia-Ming [US/US]; 380 Shad Court, Foster City, CA 94404 (US). JONA, Janan [US/US]; 125 Connemara Way #168, Sunnyvale, CA 94087 (US). JOSHI, Priti [IN/US]; 5919 Royal Ann Drive, San Jose, CA</p>												
<p>(54) Title: POLYURETHANE HYDROGEL DRUG RESERVOIRS FOR USE IN TRANSDERMAL DRUG DELIVERY SYSTEMS</p>												
<p>(57) Abstract</p> <p>High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are hydrogels formulated from polyurethanes crosslinked with diisocyanate crosslinking agents or cured with radiation in the presence of a photoinitiator. Drug loading as high as 65 to 70 wt.% or higher can be achieved by absorbing drug formulation into the reservoir after hydrogel synthesis. Methods for making and using transdermal systems containing such reservoirs are provided as well.</p>												

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroun	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

POLYURETHANE HYDROGEL DRUG RESERVOIRS FOR USE IN TRANSDERMAL DRUG DELIVERY SYSTEMS

10 Technical Field

This invention relates generally to transdermal drug delivery, and more particularly relates to polyurethane hydrogel drug reservoirs for incorporation into transdermal drug delivery systems.

15 The invention further relates to transdermal drug delivery systems containing the hydrogel reservoirs, and to methods for manufacturing and using the new transdermal systems.

20 Background

The delivery of drugs through the skin provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of 25 absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveniences -- e.g., gastro-intestinal irritation and the like -- are eliminated as well. Transdermal drug delivery also makes possible a high degree of 30 control over blood concentrations of any particular drug.

Skin is a structurally complex, relatively thick membrane. Molecules moving from the environment into and through intact skin must first penetrate the 35 stratum corneum. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be

so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex phenomenon. However, it is the cells of the stratum 5 corneum which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is 10 believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration.

Relatively recent advances in transdermal 15 drug delivery have enabled effective administration of a variety of drugs through the skin. These advances include the development of a number of skin penetration enhancing agents, or "permeation enhancers," to increase the permeability of the skin 20 or mucosal tissue, as well as non-chemical modes for facilitating transdermal delivery, e.g., the use of iontophoresis, electroporation or ultrasound. Nevertheless, the number of drugs that can be safely and effectively administered through the skin, without 25 concomitant problems such as irritation or sensitization, remains limited.

The present invention is directed to transdermal drug delivery using "high capacity" 30 hydrogel drug reservoirs into which a far greater quantity of drug may be present than possible with conventional transdermal systems. Thus, greater quantities of drug may be delivered, at higher fluxes. In addition, the high capacity drug reservoirs, also 35 reduce or in some cases eliminate the need for permeation enhancers. Further, smaller transdermal patches may be made using the inventive technology, i.e., patches that are at least as effective as prior

patches in terms of overall drug release and drug flux, but are significantly reduced in terms of size.


While hydrogels have been described as potentially useful in drug delivery systems (see,

5 e.g., P.I. Lee, *J. Controlled Release* 2:277-288 (1985)), their use in transdermal systems, and particularly the use of polyurethane hydrogels, is believed to be novel. None of the art of which 10 applicants are aware describes transdermal drug delivery system having high capacity, polyurethane hydrogel drug reservoirs, nor does the art disclose methods for manufacturing such systems as disclosed and claimed herein.

15 The invention may be used to deliver a wide variety of drugs. For example, the present drug delivery systems may be used in the transdermal administration of 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine, also known as "olanzapine." The drug is described in U.S. 20 Patent No. 5,229,382 to Chakrabarti et al., issued July 20, 1993, and assigned to Lilly Industries Limited.

25

30



Olanzapine

35 Olanzapine is an antagonist of dopamine at the D-1 and D-2 receptors, and in addition has antimuscarinic anticholinergic properties and antagonist activity at

5HT-2 receptor sites and at noradrenergic α -receptors (Moore et al., *J. Pharmacol. Exp. Ther.* 262(2):545-551 (1992)). The drug has relaxant, anxiolytic and anti-emetic properties, and, as explained in the 5 Chakrabarti et al. patent, is useful in the treatment of psychosis, acute mania and mild anxiety states, and is particularly useful in the treatment of schizophrenia and schizophreniform illnesses.

Currently, olanzapine is administered orally 10 or by injection. While the drug has been established as an effective antipsychotic agent, drug non-compliance is a serious problem, and is believed to account for approximately one-third of all short-stay hospital costs. Transdermal administration of 15 olanzapine or a pharmaceutically acceptable salt thereof, significantly enhances patient compliance by providing an advanced delivery system useful for administering the drug over an approximately three- to seven-day period. There are a number of other 20 advantages to administering olanzapine transdermally as well: gastrointestinal and other side effects associated with oral administration are substantially avoided; continuous delivery provides for sustained blood levels; the transdermal patch is easily 25 removable if any side effects do occur; and the likelihood of patient acceptance is significantly improved. In general, steady-state, transdermal delivery of the drug seems to provide a far better side effect profile overall than is associated with 30 oral administration.

The present systems are also useful in the, 35 transdermal administration of steroid drugs, including androgenic agents. Particular compounds of interest are testosterone and pharmaceutically acceptable esters and derivatives thereof. Such agents are, useful in a variety of applications, e.g., in treating hypogonadism, hypopituitarism, Addison's disease,

5 impotence, male infertility disorders, anemia, and in male hormone replacement therapy. The invention also involves the transdermal administration of androgenic agents in combination with estrogens, in treating, for example, menopause, osteoporosis, or other conditions for which estrogen-androgen combination therapy is indicated.

10 Transdermal delivery of androgens, alone or in combination with estrogenic agents, has been described. See, e.g., U.S. Patent No. 4,704,282 to Campbell et al., U.S. Patent No. 4,867,982 to Campbell et al., U.S. Patent No. 5,094,857 to Luderschmidt, U.S. Patent No. 5,152,997 to Ebert et al., U.S. Patent No. 5,460,820 to Ebert et al., and PCT Publication No. 15 WO95/03764. In contrast to prior systems for administering these drugs transdermally, however, the present invention is directed transdermal systems in which the androgenic agent is contained within drug reservoirs into which a far greater quantity of drug 20 may be loaded than possible with conventional transdermal systems. As explained above, such systems provide a number of advantages, including delivery of greater quantities of drug, at higher fluxes, reduction of patch size, and the like.

25

Disclosure of the Invention

30 Accordingly, it is a primary object of the present invention to provide a high capacity, polyurethane hydrogel drug reservoir for transdermal administration of a drug formulation contained therein.

35 It is another object of the invention to provide a transdermal drug delivery system containing a high capacity, polyurethane hydrogel drug reservoir.

It is still another object of the invention to provide a method for making such a drug delivery system.

It is a further object of the invention to provide a method for administering a drug to an individual using the novel reservoirs and transdermal drug delivery systems containing them.

5 Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the
10 invention.

The present invention is thus directed in part to high capacity, polyurethane hydrogel reservoirs useful in transdermal drug delivery systems, which, by virtue of the novel reservoirs, are
15 able to deliver greater quantities of drug, at higher fluxes, than possible with conventional transdermal systems. The hydrogel reservoirs may also reduce or in some cases eliminate the need for permeation enhancers. For those drugs which do still require the
20 presence of an enhancer to achieve high flux, the hydrogel reservoirs provide a means whereby augmented loading of both drug and enhancer may be achieved.

Transdermal drug delivery systems containing the novel reservoir will generally comprise a
25 laminated composite of at least: (a) a backing layer that is substantially impermeable to the drug and defines the upper surface of the system during drug delivery; and (b) the high capacity reservoir in the form of a polyurethane hydrogel having a predetermined quantity of a drug formulation contained therein. The hydrogel may have sufficient tack to enable the transdermal system to adhere to the skin or mucosal tissue; however, in some cases, it may be necessary to incorporate an added means for affixing the composite
30 to the body surface, typically either an "in-line" contact adhesive in the form of a layer underlying the
35

entire surface of the system, or a peripheral adhesive ring.

Additional materials and components may also be present. For example, in some cases, it may be

5 preferable or necessary to incorporate a rate-controlling membrane into the transdermal system. One or more additional reservoir and/or adhesive layers may also be included. Also, during storage and prior to use, a release liner should be present to protect
10 the basal surface of the system.

The invention is also directed to a method

for preparing a transdermal drug delivery system having a high capacity, polyurethane hydrogel drug reservoir, comprising: (a) reacting a polyurethane

15 with a crosslinking agent in the presence of water, for a time period effective to form a hydrogel; (b) absorbing a drug formulation into the hydrogel to form a drug-containing hydrogel; and (c) laminating a backing layer to the hydrogel that is substantially
20 impermeable to the drug and serves as the upper surface of the system during drug delivery. Steps (a) and (b) may be conducted simultaneously, although it is preferred, to achieve higher drug loading, that step (b) follow step (a).

25 The invention further provides a method for transdermally administering a drug to a mammalian individual, comprising positioning topically on the individual a transdermal drug delivery system containing a high capacity drug reservoir of a
30 polyurethane hydrogel as provided herein.

The systems are useful, for example, in the transdermal administration of androgenic agents such as testosterone. Administration is conducted for a time period and at an administration rate effective to

35 provide the necessary therapy, e.g., treatment of impotence, infertility disorders, or the like. Using high capacity, polyurethane hydrogel reservoirs,

transdermal patches on the order of 30 cm² or smaller may be used to deliver the selected androgenic agent, while still achieving a drug flux that is for all contemplated indications more than sufficient.

5 optimally, the androgenic agent patches are designed to be worn for 24-hour periods.

The systems are also useful in transdermally administering olanzapine or a pharmaceutically acceptable salt thereof, to treat an individual 10 suffering from or susceptible to psychosis, acute mania or mild anxiety states, particularly schizophrenia and schizophreniform illnesses.

Transdermal administration of olanzapine is conducted for a time period and at an administration rate

15 effective to alleviate the symptoms at issue. The preferred transdermal system used for administration of olanzapine or a pharmaceutically acceptable salt thereof is as described above, i.e., it will typically be a laminated composite comprised of a backing layer, 20 the high capacity, polyurethane hydrogel reservoir, a means for affixing the composite to the selected area of body surface, and, optionally, other membranes and components as well. The transdermal system is preferably constructed such that an effective dose of 25 olanzapine or a pharmaceutically acceptable acid addition salt thereof will be delivered for a period in the range of about three to seven days.

Brief Description of the Drawings

30 FIG. 1 illustrates in schematic form one embodiment of a transdermal drug delivery system which can be used in conjunction with the manufacturing methodology and hydrogel reservoirs of the invention.

35 FIGS. 2 and 3 are graphs illustrating olanzapine flux obtained using the hydrogel systems prepared in Examples 1 and 2, respectively.

FIG. 4 represents in graph form the testosterone flux profiles from the hydrogel systems of the invention as evaluated in Example 3.

5 FIG. 5 represents in graph form the cumulative permeation of testosterone from hydrogel systems of the invention as evaluated in Example 3.

Modes for Carrying Out the Invention

10 Before describing the present invention in detail, it is to be understood that this invention is not limited to particular transdermal drug delivery system configurations, particular drug/vehicle formulations, or the like, as such may vary. It is also to be understood that the terminology used herein 15 is for the purpose of describing particular embodiments only, and is not intended to be limiting.

20 It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a permeation enhancer" 25 includes a mixture of two or more permeation enhancers, reference to "an excipient" or "a vehicle" includes mixtures of excipients or vehicles, reference to "an adhesive layer" includes reference to two or more such layers, and the like.

30 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred 35 materials and methods are described herein.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

By "transdermal" delivery, applicants intend 5 to include both transdermal (or "percutaneous") and transmucosal administration, i.e., delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream. The term "body surface" will sometimes be used herein to refer to either the skin 10 or the mucosal tissue.

By a "high capacity" drug reservoir, as used herein, is meant a drug reservoir containing a quantity of drug or drug formulation which is greater than that which is typically possible using 15 conventional manufacturing techniques or transdermal drug delivery systems; the drug reservoirs herein can be made so as to contain on the order of 65 wt.% to 70 wt.% drug formulation or more.

The term "hydrogel" is used in its 20 conventional sense to refer to a water-swellable polymeric matrix in which a dispersed, polymeric phase has combined with a continuous, aqueous phase to form a viscous, colloidal product.

The term "urethane" is used herein in its 25 conventional sense to denote organic compounds containing a recurring -O-(CO)-NH- linkage. The term "polyurethane" is intended to mean a polymer, either a homopolymer or copolymer, containing a plurality of urethane units as just defined.

By an "effective" amount of a drug is meant 30 a nontoxic but sufficient amount of the drug to provide the desired therapeutic or prophylactic effect. With respect to olanzapine, for example, an "effective" amount of drug refers to that dose of drug 35 which will be effective in relieving or preventing symptoms of psychosis, acute mania, mild anxiety, or the like. An "effective" amount of a permeation

enhancer as used herein means an amount that will provide the desired increase in the permeability of the skin or mucosal tissue, and, correspondingly, the desired depth of penetration, rate of administration, 5 and amount of drug delivered.

By "predetermined area of skin" is intended a defined area of intact unbroken living skin or mucosal tissue. That area will usually be in the range of about 5 cm² to about 150 cm², more usually in 10 the range of about 5 cm² to about 100 cm², and preferably in the range of about 5 cm² to about 60 cm². However, it will be appreciated by those skilled in the art of transdermal drug delivery that the area of 15 skin or mucosal tissue through which drug is administered may vary significantly, depending on patch configuration, dose, and the like. Also, above, the present technology enables preparation of generally smaller patches, typically in the range of 20 about 5 cm² to about 50 cm².

"Penetration enhancement" or "permeation enhancement" as used herein relates to an increase in the permeability of skin or mucosal tissue to a pharmacologically active agent, i.e., so as to 25 increase the rate at which the drug permeates through the body surface and enters the bloodstream. The enhanced permeation effected through the use of such enhancers can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus as described in the Examples 30 herein.

"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, 35 liquid diluent, solubilizer, or the like, which is nontoxic and which does not interact with other

components of the composition in a deleterious manner. Examples of suitable carriers for use herein include water, silicone, liquid sugars, waxes, petroleum jelly, and a variety of other materials. The term 5 "carrier" or "vehicle" as used herein may also refer to stabilizers, crystallization inhibitors, or other types of additives useful for facilitating transdermal drug delivery.

By the term "saturated," as used in 10 conjunction with the transdermal delivery of androgenic agents, is meant a pharmaceutical formulation in which the drug is present at saturation; when the present systems are used for the administration of an androgenic agent, the drug is 15 present in the pharmaceutical formulation contained in the drug reservoir at or above saturation.

When transdermal administration of 20 "olanzapine" per se is indicated herein, it is to be understood that the described method, formulation or system extends to pharmaceutically acceptable acid addition salts as well.

The drug reservoirs of the present 25 transdermal drug delivery systems are polyurethane hydrogel matrices. Generally, these matrices are formed by admixing a polyurethane with a suitable crosslinking agent in the presence of water. Drug formulation may be incorporated during hydrogel manufacture, i.e., admixed with the polyurethane along with the crosslinking agent and water, or it may be 30 incorporated into the hydrogel matrix after addition of water.

Suitable polyurethanes useful for forming 35 the hydrogel reservoir may be chemically synthesized using conventional techniques known to those skilled in the art or described in the pertinent literature. The polyurethanes can be polyurethane elastomers such as those available as Airthane®, Polathane®,

Ultracast and Cyanaprene from Air Products and Chemicals Inc., as Conathane® from Conap, Inc., as Bayte C®, Baymidur Vul Kollan®, Baydur®, Bayflex® or Baygal® from Miles Inc., Polymers, Division;

5 alternatively, polyurethane resins such as Desmodur® or Mondur® resins, which can be obtained from Miles, Inc., Industrial Chemicals Division, can be used. Hydrophilic polyurethane prepolymers such as those available under the Hypol® trademark from W.R. Grace & 10 Co., Organic Chemicals Division, may be used as well, and are particularly preferred; and an example of a particularly effective commercially available polyurethane that can be used in conjunction with the present invention is Hypol® PreMA G-50 polymer, 15 available from the Hampshire Chemical Corporation.

In order to form the hydrogel, as explained above, a crosslinking agent is added to the polyurethane in the presence of water. Preferred crosslinking agents are diisocyanates, including 20 aliphatic, cycloaliphatic and aromatic diisocyanates. Suitable diisocyanates include, but are not limited to, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethylene diisocyanate, trimethylhexamethylene diisocyanate, cyclohexyl-1,2-diisocyanate, cyclohexylene-1,4-diisocyanate, 2,4-toluene diisocyanate, and 2,6-toluene diisocyanate. 25 The amount of crosslinking agent used will be such that it is effective to produce the desired hydrogel, but preferably less than that which would result in 30 any unconsumed material. However, if excess crosslinking agent is present after hydrogel formation, it may be removed using a simple washing step.

Generally, the reaction mixture for forming 35 the polyurethane hydrogel will contain about 5 wt.% to 25 wt.% isocyanate crosslinking agent and about 0.01 wt.% to 15 wt.% water, with the polyurethane

representing the remainder of the composition, along with the drug formulation, if it is incorporated during manufacture. It will be appreciated by those skilled in the art, however, that the various

5 components of the reservoir may need to be varied, e.g., depending on the degree of tack desired (which would in turn necessitate a higher fraction of water) or on some other desired characteristic of the final product.

10 The drug formulation may be incorporated into the hydrogel during hydrogel formation or subsequent thereto. Generally, the latter procedure is preferred, as a greater degree of drug may be incorporated into the hydrogel; that is, by absorbing 15 drug into the hydrogel after the hydrogel is prepared, drug loading of at least about 40 wt.%, and preferably on the order of 65 wt.% to 70 wt.% or higher can be achieved.

20 In an alternative embodiment, a photocurable polyurethane is used at the outset, to form the hydrogel. In such a case, curing may be effected using radiation of a suitable wavelength, rather than a crosslinking agent. Photocuring can in some cases be neater, and done more rapidly, than curing using a 25 diisocyanate-type crosslinking agent. With photocuring, it is typically necessary to carry out the curing step in the presence of a photoinitiator. Suitable photoinitiators are radical photoinitiators that are well known to those skilled in the art.

30 Examples of such photoinitiators include α -alkoxy deoxybenzoins, α,α -dialkoxy deoxybenzoins, α,α -dialkoxy acetophenones, 2-hydroxy-2,2-dialkyl acetophenones, benzophenones, thioxanthones, benzils, and other compounds identified by H.J. Hageman et al., 35 "Photoinitiators and Photocatalysts for Various Polymerisation and Crosslinking Processes," in

Radiation Curing of Polymers II, ed. D.R. Randell (The Royal Society of Chemistry, 1991), at pp. 46-53.

The reservoir layer will generally although not necessarily range in thickness from about 1 to 5 about 100 mils, preferably in the range of approximately 25 to 60 mils. It will be appreciated that the thickness of the reservoir will depend, however, on a variety of considerations, including the quantity of drug to be incorporated in the reservoir, 10 desired patch size, and the like.

After fabrication of the hydrogel reservoir and incorporation of drug therein, the remainder of the transdermal system is manufactured. It will be appreciated by those skilled in the art that any 15 number of patch configurations may be used in conjunction with the present drug reservoirs; the following structures are described by way of example only, and are not intending to be limiting.

Generally, although not necessarily, a 20 backing layer is laminated to the hydrogel reservoir following reservoir preparation. The backing layer functions as the primary structural element of the system and provides the system with much of its flexibility, drape and, preferably, occlusivity. The 25 material used for the backing layer should be inert and incapable of absorbing drug, enhancer or other components of the pharmaceutical composition contained within the system. The backing is preferably made of one or more sheets or films of a flexible elastomeric 30 material that serves as a protective covering to prevent loss of drug and/or vehicle via transmission through the upper surface of the system, and will preferably impart a degree of occlusivity to the system, such that the area of the skin covered on 35 application becomes hydrated. The material used for the backing layer should permit the system to follow the contours of the skin and be worn comfortably on

areas of skin such as at joints or other points of flexure, that are normally subjected to mechanical strain with little or no likelihood of the system disengaging from the skin due to differences in the 5 flexibility or resiliency of the skin and the system. Examples of materials useful for the backing layer are polyesters, polyethylene, polypropylene, polyurethanes and polyether amides. The layer is preferably in the range of about 15 microns to about 250 microns in 10 thickness, and may, if desired, be pigmented, metallized, or provided with a matte finish suitable for writing.

Underneath the hydrogel reservoir, i.e., on the "skin" side thereof, may be a pharmaceutically 15 acceptable contact adhesive for affixing the system to the skin during drug delivery. With hydrogels which adhere well to the skin or mucosal tissue, use of a contact adhesive is unnecessary. Most hydrogels, however, will not adhere sufficiently, and a contact 20 adhesive or some other means for maintaining the system in drug transmitting relationship to the skin is required. If a contact adhesive is used, it may be in the form of a layer which covers the entire drug reservoir, thus serving as the basal surface of the 25 system during use, or it may be in the form of a peripheral ring. Suitable contact adhesive materials are pressure-sensitive adhesives suitable for long-term skin contact, which are also be physically and chemically compatible with the drug formulation, i.e., 30 the drug itself and any carriers and vehicles employed. It is essential that the contact adhesive not comprise a drug-absorbent material, as such a material would inhibit drug flux. Preferred materials for this layer include, for example, polysiloxanes, 35 polyisobutylenes, polyacrylates, polyurethanes, plasticized ethylene-vinyl acetate copolymers, low molecular weight polyether amide block polymers (e.g.,

PEBAX), tacky rubbers such as polyisobutene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and mixtures thereof.

It may also be desirable to include a rate-controlling membrane in between the drug reservoir and a contact adhesive layer, when one is present. Representative materials useful for forming rate-controlling membranes include polyolefins such as polyethylene and polypropylene, polyamides, polyesters, ethylene-ethacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl methylacetate copolymer, ethylene-vinyl ethylacetate copolymer, ethylene-vinyl propylacetate copolymer, polyisoprene, polyacrylonitrile, ethylene-propylene copolymer, and the like. Generally, a preferred material useful to form the rate-controlling membrane is ethylene-vinyl acetate copolymer. The particular material selected will be such that the flux of drug component or of one or more non-drug components, i.e., will be controlled as desired.

Additionally, to protect the basal surface of the system during storage and just prior to use, a release liner is provided to cover the exposed hydrogel or adhesive surface. The release liner is a disposable element, typically formed from a material impermeable to the drug, vehicle and adhesive, and which is easily stripped from the contact adhesive. Release liners are typically treated with silicone or fluorocarbons. Silicone-coated polyester is presently preferred.

An example of a laminated composite containing a hydrogel reservoir of the invention is shown in FIG. 1. The composite is generally designated 10, and comprises a backing layer 11, the hydrogel reservoir layer 12 containing drug 12a, optional rate-controlling membrane 13, optional contact adhesive layer 14, and a release liner 15. As

noted above, adhesive may also be present as a peripheral ring on the basal surface of the system.

Any number of drugs may be delivered transdermally using the reservoirs and drug delivery

5 systems of the invention, i.e., any compound suitable for transdermal or transmucosal administration which induces a desired systemic effect. Such substances include the broad classes of compounds normally delivered through body surfaces and membranes,

10 including skin. In general, this includes: anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; 15 antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; 20 xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmic; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central 25 nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; 30 sedatives; and tranquilizers. The amount of active agent incorporated into the drug reservoir will vary, depending on the agent, the intended dosage, the individual undergoing treatment, the particular indication, and the like.

35 It is important to note that the present invention enables transdermal delivery of drugs which typically display low skin flux, as the quantity of

drug which may be loaded into the high capacity drug reservoir is significantly greater than with conventional systems. Other preferred drugs are those that require high flux to achieve a desired

5 therapeutic effect and thus may require the presence of an enhancer in the drug formulation. The present invention provides a drug reservoir comprising a polyurethane hydrogel that, for the same size patch, is capable of absorbing not only more drug than prior
10 patches but is also capable of absorbing more enhancer as well.

Steroids represent one class of drugs with which the present reservoirs and transdermal systems are particularly useful. Examples of steroid drugs

15 which may be administered in conjunction with the invention include: progestogens such as flurogestone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone,
20 norethindrone acetate, norethisterone, norethynodrel, desogestrel, 3-keto desogestrel, gestadene and levonorgestrel; estrogens such as estradiol and its esters (e.g., estradiol benzoate, valerate, cypionate, decanoate and acetate), ethynodiol diacetate, estriol,
25 estrone and mestranol; and corticosteroids such as betamethasone, betamethasone acetate, cortisone, hydrocortisone, hydrocortisone acetate, corticosterone, fluocinolone acetonide, prednisolone, prednisone and triamcinolone.

30 Also, in one specific embodiment of the invention, the present transdermal systems are used to administer androgenic agents such as the naturally occurring androgens androsterone and testosterone; pharmaceutically acceptable esters of testosterone,
35 typically esters formed from the hydroxyl group present at C-17, and particularly the enanthate, propionate, cypionate and phenylacetate esters; and

pharmaceutically acceptable derivatives of testosterone such as methyltestosterone, testolactone, oxymetholone and fluoxymesterone. Testosterone and the 17-esters thereof, particularly the enanthate, 5 propionate and cypionate esters, are preferred. Such agents are useful in a variety of applications, e.g., in male hormone therapy, in treating hypogonadism, hypopituitarism, Addison's disease, impotence, male infertility disorders, anemia, and the like. Other 10 pharmaceutically active agents, particularly additional steroidal agents, may be administered along with the selected androgenic agent. These agents will generally be estrogens and/or progestogens. The amount of each such additional agent incorporated into 15 the drug reservoir will vary, depending on the intended dosage. Normally, the daily dosage of estrogenic agent will be at least about 0.03 mg/day, while the daily dosage of progestogen will be at least about 0.2 mg/day, depending, of course, on the 20 particular estrogen and progestogen to be administered. Administration of an androgenic agent in combination with an estrogen and/or a progestogen is useful, for example, in the treatment of menopausal symptoms, osteoporosis, or other conditions for which 25 such combination therapy is indicated.

When the present invention is used in conjunction with the delivery of androgenic agents, administration is conducted for a time period and at an administration rate effective to provide the 30 necessary therapy, e.g., treatment of impotence, infertility disorders, or the like. The agent should be delivered at a dosage of at least about 3 mg/day, more preferably at least about 6 mg/day. Transdermal patches on the order of 30 cm² or smaller may be used 35 to deliver the selected androgenic agent, while still achieving a drug flux that is for all contemplated indications more than sufficient. Generally, a flux

of at least about 100, more preferably at least about 200 $\mu\text{g}/\text{cm}^2/\text{day}$, is necessary. The present drug reservoirs achieve such fluxes. Optimally, the androgenic agent patches are designed to be worn for 5 24-hour periods.

While not essential, it is preferred that transdermal administration of androgenic agents be conducted at or above saturation. That is, the androgenic agent is present at or above saturation 10 with respect to its concentration in the formulation contained in the drug reservoir.

The reservoirs and transdermal systems of the invention are also useful in the transdermal administration of olanzapine. The specific method and 15 drug delivery system for delivering olanzapine transdermally may vary, but necessarily involve application of a drug delivery system containing olanzapine or a pharmaceutically acceptable acid addition salt thereof to a predetermined area of the 20 skin or mucosal tissue at an administration rate and for a period of time sufficient to provide an effective blood level of drug for a desired period of time. The drug is present in a high capacity, superabsorbent drug reservoir within a transdermal 25 delivery system such as the exemplary system described above. It should be noted that this embodiment of the invention, while primarily directed to the treatment of individuals suffering from or susceptible to psychosis, acute mania or mild anxiety states, may 30 extend to any use of olanzapine deriving from its activity an antagonist of dopamine at the D-1 and D-2 receptors, its antimuscarinic anti-cholinergic properties, and/or its antagonist activity at 5HT-2 receptor sites and noradrenergic α -receptors. The 35 transdermal olanzapine system formulated using the novel reservoirs are preferably constructed so that an effective dose of olanzapine or a pharmaceutically

acceptable salt thereof will be delivered for a period in the range of about three to seven days.

Olanzapine or any other basic drug may be administered in the form of the base or as a

5 pharmaceutically acceptable acid addition salt. As will be appreciated by those skilled in the art, the base form of the drug can be converted to an acid addition salt by treatment with a stoichiometric excess of a selected acid. Such acid addition salts
10 may be formed, for example, with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid,
15 malonic acid, succinic acid, maleic acid, hydroxymaleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, naphthalene-2-sulfonic acid,
20 salicylic acid and the like.

Similarly, acidic drugs may be administered in the acid form or, as will be appreciated by those skilled in the art, as a pharmaceutically basic salt.

The salts may be derived from inorganic bases, e.g.,
25 the ammonium, potassium, sodium, calcium and magnesium salts. Alternatively, the salts may be derived from pharmaceutically acceptable nontoxic bases, including isopropylamine, trimethylamine, dimethylamine, triethylamine, ethanolamine, dicyclohexylamine,
30 choline, tromethylamine, and the like.

The high capacity hydrogel reservoirs of the invention may in some cases eliminate the need for a permeation enhancer. However, enhancers may still be preferred or even required for administering certain
35 drugs, e.g., steroids, including androgenic agents, and olanzapine. Suitable enhancers include, but are not limited to, dimethylsulfoxide (DMSO), dimethyl

formamide (DMF), N,N-dimethylacetamide (DMA),
decylmethylsulfoxide (C₁₀MSO), polyethylene glycol
monolaurate (PEGML), propylene glycol (PG), propylene
glycol monolaurate (PGML), glycerol monolaurate (GML),
5 methyl laurate (ML), lauryl lactate (LL), isopropyl
myristate (IPM), terpenes such as menthone, C₂-C₆
diols, particularly 1,2-butanediol and 1,3-butanediol
(1,2-BD and 1,3-BD), lecithin, the 1-substituted
azacycloheptan-2-ones, particularly 1-n-
10 dodecylcyclazacycloheptan-2-one (available under the
trademark Azone® from Whitby Research Incorporated,
Richmond, VA), alcohols, and the like. Vegetable oil
permeation enhancers, as described in commonly
assigned U.S. Patent No. 5,229,130 to Sharma, may also
15 be used. Such oils include, for example, safflower
oil, cotton seed oil and corn oil.

Preferred enhancers for use in conjunction
with the present invention, and particularly in the
transdermal administration of androgenic agents and
20 olanzapine, are esters given by the formula
[CH₃(CH₂)_mCOO]_nR in which m is an integer in the range
of 8 to 16, n is 1 or 2, and R is a lower alkyl (C₁-C₃)
residue that is either unsubstituted or substituted
25 with one or two hydroxyl groups. In the preferred
embodiment herein, the ester component is a lower
alkyl (C₁-C₃) laurate (i.e., m is 10 and n is 1), and
in a particularly preferred case is "PGML." It will
be appreciated by those skilled in the art that the
30 commercially available material sold as "PGML" is
typically a mixture of propylene glycol monolaurate
itself, propylene glycol dilaurate, and either
propylene glycol, methyl laurate, or both. Thus, the
terms "PGML" or "propylene glycol monolaurate" as used
35 herein are intended to encompass both the pure
compound as well as the mixture that is typically
obtained commercially.

Also preferred are fatty acids and fatty alcohols corresponding to the above-defined fatty esters. Thus, fatty acids useful as permeation enhancers herein will generally have the formula

5 $\text{CH}_3(\text{CH}_2)_m\text{COOH}$, where m is as above, while the fatty alcohols will have the formula $\text{CH}_3(\text{CH}_2)_m\text{CH}_2\text{OH}$.

Other preferred enhancer compositions are wherein a fatty ester as described above is combined with an ether component selected from the group 10 consisting of diethylene glycol monoethyl ether and diethylene glycol monomethylether. Such enhancer compositions are described in detail in U.S. Patent Nos. 5,053,227 and 5,059,426 to Chiang et al., both of common assignment herewith.

15 Particularly preferred permeation enhancers are selected from the group consisting of $\text{C}_2\text{-C}_6$ alkanediols, fatty esters having the structural formula $[\text{CH}_3(\text{CH}_2)_m\text{COO}]_n\text{R}$, fatty acids having the 20 structural formula $\text{CH}_3(\text{CH}_2)_m\text{COOH}$, fatty alcohols having the structural formula $\text{CH}_3(\text{CH}_2)_m\text{CH}_2\text{OH}$, and mixtures thereof, where m and n are as defined above. It has been found that ternary vehicle combinations in which such a fatty alcohol or acid is combined with a 25 fatty ester and a $\text{C}_2\text{-C}_6$ alkanediol, e.g., 1,2-butenediol, 1,3-butanediol, and the like, are particularly effective enhancer compositions for use in conjunction with the present invention.

If an enhancer is used, the type and amount 30 of enhancer will similarly depend on a number of factors, e.g., the strength of the particular enhancer, the desired increase in skin permeability, rate of administration, and amount of drug delivered.

The drug formulations contained in the high 35 capacity reservoirs may also include standard carriers or vehicles useful for facilitating drug delivery,

e.g., stabilizers, antioxidants, anti-irritants and crystallization inhibitors.

Preferred drug formulations, i.e., the drug-containing composition which is loaded into the drug reservoir, will typically contain on the order of about 0.1 wt.% to 20 wt.%, preferably about 1 wt.% to 10 wt.% drug, with the remainder of the formulation representing other components such as enhancers, vehicles or the like. If enhancers are present, they will generally represent on the order of approximately 1 wt.% to 25 wt.% of the drug formulation.

15 It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the description above as well as the examples which follow are intended to illustrate and not limit the scope of 20 the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

25 In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric.

30

Experimental

Materials: Olanzapine free base was provided by Eli Lilly. Testosterone was purchased from Sigma Chemical Company and used as received. All 35 chemicals used were of reagent grade.

Preparation of Transdermal Systems: Drug was dissolved in selected vehicle combinations as

indicated in the Examples below. Hydrogels were prepared as indicated in the individual examples, and cut into disks which were then applied to the skin.

Assay methodology: For evaluation of skin flux, samples were analyzed by HPLC using UV-detection at 265 nm and 220 nm. Chromatographic resolution was achieved using a Brownlee RP-18 column, 100 mm x 4.6 mm, with a 5 μ m particle size (for olanzapine), and a Zobrax C₈ column, 250 mm x 4.6 mm, also with a 5 μ m particle size (for testosterone), run at a flow rate of 1.5 ml per min (olanzapine) or 1.0 ml per minute (testosterone) at ambient temperature. The mobile phase was a mixture of 47%-48% acetonitrile: 52%-53% water. The retention time for olanzapine was about 3.0 min; the retention time for testosterone was about 4.0 min.

In Vitro Skin Permeation of Drug:

Skin Preparation: Human cadaver skin was used for the permeation studies. The frozen skins were thawed and the epidermal layers (stratum corneum and viable epidermis) were separated from the full-thickness skin by immersing it in water at 60°C for two min. This epidermis was either used immediately for flux studies or stored at -20°C for later studies.

Skin permeation from prototypes: Modified Franz cells were used for evaluating the prototype systems for delivery of drug. Prototype systems, prepared as described above, were placed on top of the epidermis. Gentle pressure was applied to ensure full contact between the prototype and the stratum corneum. The skin membrane with the prototype system was then mounted carefully between the donor and the receiver compartments. The receiver compartment was filled with 7.5 ml of pH 7.4 buffer and the temperature was maintained at 32°C \pm 1°C throughout the experimental period. The entire receiver content was withdrawn and

replaced with fr sh buffer. Samples were assayed by HPLC.

5 Data Analysis: Skin flux ($\mu\text{g}/\text{cm}^2/\text{hr}$) was determined at each time point by dividing the amount of drug penetrating the skin during that period of time corrected for the surface area by the duration of time.

Example 1

10 Olanzapine was dissolved in a combination of vehicles (see Table 1), added with water to Hypol® PreMA G-50 polymer (Hampshire Chemical Corporation) (the ratio of water to polymer was approximately 2:1) and mixed together until a hydrogel was formed. The 15 gel was cut into 2 cm^2 area circles and applied onto human cadaver skin using a Franz diffusion cell. At predetermined times, the receiver fluid was replaced with fresh fluid and analyzed for olanzapine using HPLC. The formulations evaluated are listed in Table 20 1 and the skin flux results are shown in FIG. 2.

Table 1	
Formulation	
25	1. Hydrogel G-50 contains 25% Solution of saturated olanzapine in (10% Methyl Laurate + 45% Lauryl lactate + 45% 1,2-butanediol)
30	2. Hydrogel G-50 contains 25% Solution of saturated olanzapine in (10% Lauric acid + 45% Lauryl lactate + 45% 1,2-butanediol)

Example 2

15 Olanzapine was dissolved in a combination of vehicles (as indicated in Table 2). Water was added
5 to Hypol® PreMA G-50 polymer, as above (the ratio of water to polymer used was again approximately 2:1) and the solution mixed until a hydrogel was formed. The gel was cut into 2 cm² circles which were then soaked
10 with drug formulations overnight. The final product was applied onto human cadaver skin, as in Example 1. The formulations are listed in Table 2 and the results are shown in FIG. 3.

15

Table 2	
Formulation	
1.	Olanzapine saturated in 10% Lauric acid + 45% methyl Laurate + 45% 1,2-butanediol and left overnight with Hypol PreMA gel.
2.	Olanzapine saturated in 10% Oleic acid + 45% methyl Caprate + 45% 1,2-butanediol and left overnight with Hypol PreMA gel.

20

25

A skin flux study was conducted to evaluate the flux of testosterone from polyurethane hydrogel systems. Testosterone was dissolved in a combination of vehicles (see Table 3), added with water to Hypol® PreMA G-50 polymer, as in the preceding examples (the ratio of water to polymer was again approximately 2:1) and mixed together until a hydrogel was formed.

30

35

The formulations evaluated are listed in Table 3, along with the cumulative permeation results from various platforms. The results are also illustrated graphically in FIGS. 4 and 5.

5

10

Table 3 Cumulative Permeation of Testosterone from Platforms at 24 Hours			
	Formula-tion #	Platform	Om (μ g/cm ²)
	1.	Hydrogel (Lauric Acid:ML:BD 20:40:40)	198 \pm 74
	2.	Hydrogel (Lauryl Alcohol:ML:BD 20:40:40)	127 \pm 58
	3.	Hydrogel (Benzyl Alcohol:MD:BD 20:40:40)	181 \pm 28

15

20

25

30

35

Claims:

1. A drug reservoir for use in a
5 transdermal drug delivery system, comprising a layer
of a polyurethane hydrogel having a drug formulation
absorbed therein.
2. The drug reservoir of claim 1,
10 containing at least about 40 wt.% drug formulation.
3. The drug reservoir of claim 2,
containing at least about 65 wt.% drug formulation.
- 15 4. The drug reservoir of claim 1, wherein
the drug is a steroid drug.
- 20 5. The drug reservoir of claim 1, wherein
the drug formulation further comprises a permeation
enhancer.
- 25 6. A transdermal drug delivery system,
comprising a laminated composite of:
a high capacity drug reservoir of a
polyurethane hydrogel having a drug formulation
contained therein; and
a backing layer that is substantially
impermeable to the drug and which defines the upper
surface of the system during drug delivery.
30
- 35 7. The system of claim 6, wherein the drug
reservoir contains at least about 40 wt.% drug
formulation.
8. The system of claim 7, wherein the drug
reservoir contains at least about 65 wt.% drug
formulation.

9. The system of claim 6, further including a rate-controlling membrane disposed between the drug reservoir and the contact adhesive layer.

5 10. The system of claim 6, wherein the drug is a steroid drug.

11. The system of claim 6, wherein the drug formulation further comprises a permeation enhancer.

10 12. A method for preparing a transdermal drug delivery system having a high capacity, polyurethane hydrogel drug reservoir, comprising: (a) reacting a polyurethane with a crosslinking agent in 15 the presence of water, for a time period effective to form a hydrogel; (b) absorbing a drug formulation into the hydrogel to form a drug-containing hydrogel; and (c) laminating a backing layer to the hydrogel that is substantially impermeable to the drug and serves as 20 the upper surface of the system during drug delivery.

13. The method of claim 12, wherein steps (a) and (b) are conducted simultaneously.

25 14. The method of claim 12, wherein step (b) is conducted subsequent to step (a).

30 15. A method for administering a drug to a mammalian individual, comprising positioning topically on the individual a transdermal drug delivery system containing the drug reservoir of claim 1.

1/4




FIG. 1




FIG. 2





FIG. 3


3 / 4



<u>FORMULATION#</u>	<u>PLATFORM</u>
1.	HYDROGEL (LAURIC ACID:ML:BD 20:40:40)
2.	HYDROGEL (LAURYL ALCOHOL:ML:BD 20:40:40)
3.	HYDROGEL (BENZYL ALCOHOL:MD:BD 20:40:40)

FIG. 4

4 / 4



<u>FORMULATION#</u>	<u>PLATFORM</u>
1.	HYDROGEL (LAURIC ACID:ML:BD 20:40:40)
2.	HYDROGEL (LAURYL ALCOHOL:ML:BD 20:40:40)
3.	HYDROGEL (BENZYL ALCOHOL:MD:BD 20:40:40)

FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/14739

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 05809 A (POLYMEDICA) 2 May 1991 see the whole document ---	1-15
Y	WO 92 20324 A (GENSIA) 26 November 1992 see the whole document ---	1-15
Y	US 5 160 328 A (J.V.CARTMELL ET AL.) 3 November 1992 see the whole document ---	1-15
Y	EP 0 528 091 A (NDM) 24 February 1993 see the whole document ---	1-15
Y	US 5 423 737 A (J.V.CARTMELL ET AL.) 13 June 1995 see the whole document -----	1-15

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'&' document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

24 February 1997

28.02.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Scarpioni, U

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 14739

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 15 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/14739

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9105809 A	02-05-91	US 5118779 A AU 6735590 A CA 2044133 A EP 0495011 A	02-06-92 16-05-91 11-04-91 22-07-92
WO 9220324 A	26-11-92	AU 2143792 A EP 0524718 A	30-12-92 27-01-93
US 5160328 A	03-11-92	AU 641322 B AU 1945792 A CA 2073274 A EP 0536875 A JP 5184621 A JP 7034812 B NZ 243404 A	16-09-93 11-02-93 08-02-93 14-04-93 27-07-93 19-04-95 26-08-94
EP 528091 A	24-02-93	AU 634432 B CA 2056598 A JP 5042179 A JP 7098051 B US 5480377 A	18-02-93 18-02-93 23-02-93 25-10-95 02-01-96
US 5423737 A	13-06-95	AU 667766 B AU 5644794 A CA 2119731 A EP 0630629 A JP 7088131 A NZ 250994 A US 5476443 A US 5489262 A US 5501661 A	04-04-96 08-12-94 28-11-94 28-12-94 04-04-95 26-09-95 19-12-95 06-02-96 26-03-96